课题基金 / 基金详情

Role and therapeutic potential of ERK3/ERK4 MAP kinases in acute kidney injury

Role and therapeutic potential of ERK3/ERK4 MAP kinases in acute kidney injury
ERK3/ERK4 MAP 激酶在急性肾损伤中的作用和治疗潜力
批准号：
358002
负责人：
Meloche Sylvain
金额：
$64.09万
依托单位：
Institute for Research in Immunology and Cancer (Montreal, QC)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2016
资助国家：
加拿大
项目状态：
已结题
起止时间：
2016-10-01 至 2021-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=358002&lang=en
关键词：
Acute Kidney Injury Chemokines Erk3/Erk4 Atypical Map Kinases Inflammation Map Kinases Mouse Models Of Disease Phosphoproteomics Signal Transduction Small Molecule Inhibitor

项目摘要

项目成果

Meloche Sylvain的其他基金

相似基金

相关文献

中文摘要
翻译
MAP是一类在控制细胞增殖、分化、迁移和适应过程中发挥重要作用的酶家族。越来越多的证据表明，这些酶与各种人类疾病的发病机制有关。
英文摘要
MAP kinases are a family of enzymes that play important roles in the control of cell proliferation, differentiation, migration and adaptation. Accumulating evidence suggests that these enzymes are implicated in the pathogenesis of various human diseases a
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression
Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4
Regulation, downstream targets and functional specificity of the MAP kinases ERK1 and ERK2
Targeting the degradation of the cyclin-dependent kinase inhibitor p21 as a novel approach to cancer therapy
海外基金